Skip to main content
To KTH's start page

Engineering and pharmacokinetic tuning of ADAPT scaffold proteins for solid tumor targeting

Time: Fri 2026-10-16 10.00

Location: F3 (Flodis), Lindstedtsvägen 26 & 28, Stockholm

Video link: https://kth-se.zoom.us/j/65773392057?pwd=rAVa1jWFNr3rbzO4RS7pTduYrSYA6L.1

Language: English

Subject area: Biotechnology

Doctoral student: Emma Larsson , Proteinteknologi

Opponent: Professor Ylva Ivarsson, Uppsala universitet, Uppsala, Sweden

Supervisor: Professor Sophia Hober, Science for Life Laboratory, SciLifeLab, Proteinteknologi

Export to calendar

QC 2026-09-23

Abstract

Targeted therapy is an important pillar in modern cancer treatment. Therapeutic antibodies are widely used for specific binding to tumor-associated targets, but they face limitations related to their large size and complex structure. Small scaffold proteins can serve as attractive alternatives or complements to therapeutic antibodies, offering advantages such as high stability, deep tumor penetration, and ease of production in bacterial systems. However, their small size also leads to rapid renal clearance, which can limit their therapeutic efficacy. In this thesis, alternative scaffold proteins based on the albumin-binding domain (ABD), called ADAPTs, were explored for their potential to balance these properties. The intrinsic albumin-binding surface of the ADAPT scaffold, together with its engineered target-binding surface, provides an opportunity to combine cancer targeting with pharmacokinetic tuning, while preserving the minimal size of the scaffold (6 kDa).

In the first part of this thesis, the bispecific ADAPT platform was explored for solid tumor targeting. In Paper I, a high-throughput phage display selection workflow was developed to facilitate rapid discovery of new binders. The established workflow was employed in Paper II to select an ADAPT with simultaneous bispecificity for albumin and folate receptor alpha (FRα), a clinically validated target in ovarian cancer. Rational design and affinity maturation resulted in ADAPT22 with subnanomolar affinity for FRα and nanomolar affinity for albumin. Evaluation in tumor-bearing mice confirmed its dual functionalities in vivo, thereby establishing simultaneous bispecific ADAPTs as a viable strategy for combining tumor targeting with half-life extension. Further, Paper III investigated albumin-binding bivalency as a strategy to further reduce the renal uptake of ADAPT22, with the aim of enabling FRα-targeted radionuclide therapy. As expected, fusion to a high-affinity ABD greatly increased the apparent albumin affinity, which translated into a prolonged half-life and reduced renal uptake in vivo. However, ABD fusion also reduced tumor uptake in FRα-positive xenografts, likely due to steric hindrance and impaired tumor penetration caused by bivalent binding to two albumin molecules. 

In the second part of this thesis, the ADAPT scaffold was explored for diagnostic imaging of FRα-positive tumors. In Paper IV, an FRα-targeting imaging agent was developed by mutational silencing of the albumin-binding surface in ADAPT22 to remove its half-life extending property. Radiolabeling via the N-terminal hexahistidine-tag yielded the imaging candidate 99mTc-ADAPT21. The imaging tracer demonstrated rapid systemic clearance, resulting in high-contrast visualization of FRα-positive tumors as early as 1 h after injection in mouse xenografts. In Paper V, the imaging properties of ADAPT21 were further improved by introducing a negatively charged peptide-based chelator (EEEC) for radiolabeling at the C-terminus. The optimized imaging candidate, 99mTc-ADAPT21-EEEC, demonstrated improved tumor-to-organ ratios across most organs. Importantly, the reduced liver uptake may facilitate the detection of hepatic metastases in ovarian cancer.

Collectively, these studies show that the intrinsic albumin-binding surface of the ADAPT scaffold can be exploited to modulate its pharmacokinetic profile according to the intended application. This versatility, combined with its exceptionally small size, supports the potential of the ADAPT platform for both therapeutic and diagnostic targeting of solid tumors.

Link to DiVA